$AXLA News
Last published 3y ago
- 3y agoAXLAAxcella Announces Reverse Stock Split Effective September 19, 2023Business Wire– AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to
- 3y agoAXLAAxcella Granted Patent for Long COVID Fatigue TreatmentBusiness WireClaims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage
- 3y agoAXLAAxcella Reports First Quarter Financial Results and Provides Business UpdateBusiness WireLong COVID Phase 2b/3 clinical trial may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial
- 3y agoAXLAAxcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023Business WireDr. Lucy E.M. Finnigan will present on the Phase 2a clinical trial of AXA1125 in Long COVID Fatigue on April 18 Dr. Finnigan will also report on AXA1125 treatment effects on biomarkers of mitochondrial energetics and
- 3y agoAXLAAxcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateBusiness WireLong COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design
- 3y agoAXLAAxcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID FatigueBusiness WirePhase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve
- 3y agoAXLAAxcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that
- 3y agoAXLAAxcella Announces Regulatory Path to Registration of AXA1125 for Long COVID FatigueBusiness WireMHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January
- 3y agoAXLAAxcella Announces Program Reprioritization and Corporate RestructuringBusiness WireMove Positions Company to Best Focus on Long COVID Program Axcella Therapeutics (NASDAQ:AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic
- 4y agoAXLAAxcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual MeetingBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that
- 4y agoAXLAAxcella Reports Third Quarter Financial Results and Provides Business UpdateBusiness WirePromising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) $34.2 Million Registered Direct
- 4y agoAXLAAxcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022Business WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that
- 4y agoAXLAAxcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that
- 4y agoAXLAAxcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board MembersBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that
- 4y agoAXLAAxcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)Business WireSubjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis Subjects with NASH experienced clinically and statis
- 4y agoAXLAAxcella Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a
- 4y agoAXLAAxcella Reports Second Quarter Financial Results and Provides Business UpdateBusiness WireAnnounced Statistically Significant Clinical Improvement in Fatigue in the Phase 2A Long COVID Trial Topline data NASH Trial interim Data Expected in Late Q3 2022 Company to Host Conference Call at 8:30 a.m. ET today Axcella Therape
- 4y agoAXLAAxcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVIDBusiness WireSubjects with Long COVID receiving AXA1125 experienced a clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects Responders to AXA1125 demonstrated significantly im
- 4y agoAXLAAxcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical PortfolioBusiness WireLong COVID Trial Topline data expected in early Q3 2022 NASH Trial interim data expected in late Q3 2022 OHE Trial Suspended Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat com
- 4y agoAXLAAxcella Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a
- 4y agoAXLAAxcella Reports First Quarter Financial Results and Provides Business UpdateBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarte
- 4y agoAXLACDAKDNLIEVLO+7Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING PlatformBusiness WireLatest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine
- 4y agoAXLACDAKDNLIEVLO+7Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of AlltrnaPR NewswireWerner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team w
- 4y agoAXLAAxcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBusiness WireCompleted $25 million registered direct stock offering priced at the market Initiated Phase 2a Long COVID clinical trial Fast Track designation received from FDA for AXA1125 in NASH with liver fibrosis Enhanced management team Long COV
- 4y agoAXLAAxcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022Business WireConference call to take place at 8:30 a.m. ET Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today
- 4y agoAXLAAxcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The MarketBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities
- 4y agoAXLACDAKDNLIEVLO+8Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory AffairsPR NewswireCAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pa
- 4y agoAXLACDAKDNLIEVLO+7INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTPR NewswireCAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental chall
- 4y agoAXLAAxcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASHBusiness WireDesignation provides the potential for an expedited drug development path EMMPACT℠ Phase 2b clinical trial enrolling well, with interim data expected in mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pio
- 4y agoAXLACDAKDNLIEVLO+8Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New MedicinesBusiness WireCompany increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity,
- 4y agoAXLAAxcella Therapeutics to Participate in the SVB Leerink Global Healthcare ConferenceBusiness WireFireside chat to be webcast at 9:20 a.m. ET on February 17 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compos
- 4y agoAXLAPYXSTSCNAxcella Therapeutics Announces Appointment of New Chief Financial OfficerBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the
- 4y agoAXLACDAKDNLIEVLO+8Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform BiologyPR NewswireCAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental StrategyPR NewswireCAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental St
- 4y agoAXLAAxcella Therapeutics Details Clinical and Operational Milestones for 2022Business WireLong COVID Phase 2a top-line data anticipated in mid-2022 EMMPACT℠ Phase 2b interim data in nonalcoholic steatohepatitis (NASH) anticipated in mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a
- 4y agoAXLAAxcella Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Off
- 4y agoAXLAAxcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical TrialBusiness WirePatient screening underway in the United Kingdom in trial to assess oral product candidate's potential to address Long COVID fatigue and muscle weakness Top-line data readout anticipated by mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clini
- 4y agoAXLACDAKDNLIEVLO+9Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of DirectorsBusiness WireEstepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity
- 4y agoAXLAAxcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical OfficerBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been p
- 4y agoAXLAAxcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare ConferenceBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will be participating
- 4y agoAXLACDAKDNLIEVLO+8Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation PlatformBusiness Wire- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly sc
- 4y agoAXLACDAKDNLIEVLO+8Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate DevelopmentPR NewswireCAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this
- 5y agoAXLAAxcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical TrialsBusiness WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarte
- 5y agoAXLACDAKDNLIEVLO+8Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic FibrosisBusiness WireTessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundatio
- 5y agoAXLAAxcella Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2021Business WireAxcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at T
- 5y agoAXLAAxcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVIDBusiness WirePotential to play leading role in addressing Long COVID fatigue and muscle weakness via AXA1125's mitochondrial and bioenergetic impact Phase 2a clinical trial to be initiated by researchers at Oxford University by year-end; top-line data readout
- 5y agoAXLAAxcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021Business WireEvent to feature an unveiling of Axcella's next clinical program, ongoing OHE and NASH programs, and platform Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogen
- 5y agoAXLACDAKDNLIEVLO+7Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate ChangePR NewswireCAMBRIDGE, Mass., Oct. 13, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into
- 5y agoAXLAAxcella Announces Upcoming Investor Conference PresentationBusiness WireH.C. Wainwright 5th Annual NASH Investor Conference fireside chat and webcast to be available on October 12 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using end
- 5y agoAXLAAxcella Announces Upcoming Investor Conference PresentationBusiness WireH.C. Wainwright 23rd Annual Global Investment Conference presentation and webcast to be available on September 13 Axcella (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health usi